Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).

Results

Title:	Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
Authors :	Kim, Sung Bae; ...; Kostic, Sanja; ...; (broj, koautora 20)
Issue Date:	2025
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Search Idenfier
Type:	Conference Paper
Collation:	vol. 43 br. 16_suppl str. 1007-1007
DOI:	10.1200/JCO.2025.43.16_suppl.1007
WoS-ID:	001509502800001
Scopus-ID:	2-s2.0-105023524562
URI:	https://enauka.gov.rs/handle/123456789/986637
Project:	DAEWHA PHARM. CO., LTD.
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

1
SCOPUS^TM

1
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall

Google Scholar^TM